Annals of Hematology

, Volume 95, Issue 4, pp 593–601 | Cite as

Clinical outcomes of primary intraocular lymphoma patients treated with front-line systemic high-dose methotrexate and intravitreal methotrexate injection

  • Wei-Li Ma
  • Hsin-An Hou
  • Ya-Jui Hsu
  • Yin-Kai Chen
  • Jih-Luh Tang
  • Woei Tsay
  • Po-Ting Yeh
  • Chung-May Yang
  • Chang-Ping Lin
  • Hwei-Fang Tien
Original Article

Abstract

A standard treatment for patients with primary intraocular lymphoma (PIOL) remains unclear. This study retrospectively analyzed the clinical features and outcomes of 19 patients with PIOL who were treated with a first-line therapy comprising combined intravenous high-dose methotrexate and intravitreal methotrexate between January 2003 and December 2013. Thirteen (68.4 %) patients were female, and the median age at diagnosis was 57 (39–77 years). Diagnoses were based on the identification of abnormal lymphoid cells in vitreous fluid. Ten (52.6 %) patients had bilateral eye involvement, and six had concurrent central nervous system (CNS) involvement. All 19 patients achieved complete remission (CR) as confirmed by cytological examination of vitreous and cerebrospinal fluid and brain imaging if CNS was involved. Patients with concurrent brain involvement required a longer time to achieve CR. However, the duration of complete remission did not differ between patients with and without CNS involvement. The 5-year overall survival rate was 55.8 % for the total cohort and was higher (68.8 %) in patients with isolated PIOL than in those with concurrent CNS involvement. In all patients, methotrexate treatment was well tolerated, with manageable side effects. We conclude that combined intravitreal methotrexate and systemic high-dose methotrexate treatment is effective in patients with PIOL.

Keywords

Methotrexate Primary intraocular lymphoma 

Notes

Acknowledgments

This work was partially sponsored by grants NSC 103-2628-B-002-008-MY3 from the National Science Council (Taiwan) and MOHW103-TD-B-111-04 and MOST 103-2923-B-002-001 from the Ministry of Health and Welfare (Taiwan).

Authors’ contributions

Contribution: W.L.M. was responsible for literature collection, data management and interpretation, statistical analysis, and manuscript writing. Y.K.C. and Y.J.H. were responsible for data management and interpretation. H.A.H. was responsible for study design, data management, statistical analysis, and manuscript writing. W.T., P.T.Y., C.M.Y., and J.L.T. contributed to patient care and clinical data. H.F.T. and C.P.L. treated patients; planned, designed, and coordinated the study throughout the study period; and wrote the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.

References

  1. 1.
    Coupland SE, Damato B (2008) Understanding intraocular lymphomas. Clin Experiment Ophthalmol 36:564–578CrossRefPubMedGoogle Scholar
  2. 2.
    Hoffman PM, McKelvie P, Hall AJ, Stawell RJ, Santamaria JD (2003) Intraocular lymphoma: a series of 14 patients with clinicopathological features and treatment outcomes. Eye 17:513–521CrossRefPubMedGoogle Scholar
  3. 3.
    Chan CC, Wallace DJ (2004) Intraocular lymphoma: update on diagnosis and management. Cancer Control 11:285–295PubMedPubMedCentralGoogle Scholar
  4. 4.
    Akpek EK, Ahmed I, Hochberg FH, Soheilian M, Dryja TP, Jakobiec FA, Foster CS (1999) Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes. Ophthalmology 106:1805–1810CrossRefPubMedGoogle Scholar
  5. 5.
    Coupland SE, Heimann H, Bechrakis NE (2004) Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features. Graefes Arch Clin Exp Ophthalmol 242:901–913CrossRefPubMedGoogle Scholar
  6. 6.
    Cassoux N, Merle-Beral H, Leblond V, Bodaghi B, Miléa D, Gerber S, Fardeau C, Reux I, Xuan KH, Chan CC, LeHoang P (2000) Ocular and central nervous system lymphoma: clinical features and diagnosis. Ocul Immunol Inflamm 8:243–250CrossRefPubMedGoogle Scholar
  7. 7.
    Mochizuki M, Singh AD (2009) Epidemiology and clinical features of intraocular lymphoma. Ocul Immunol Inflamm 17:69–72CrossRefPubMedGoogle Scholar
  8. 8.
    Goto H, Mochizuki M, Yamaki K, Kotake S, Usui M, Ohno S (2007) Epidemiological survey of intraocular inflammation in Japan. Jph J Ophthalmol 51:41–44CrossRefGoogle Scholar
  9. 9.
    Margolis L, Fraser R, Lichter A, Char DH (1980) The role of radiation therapy in the management of ocular reticulum cell sarcoma. Cancer 45:688–692CrossRefPubMedGoogle Scholar
  10. 10.
    Berenbom A, Davila RM, Lin HS, Harbour JW (2007) Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy. Eye 21:1198–1201CrossRefPubMedGoogle Scholar
  11. 11.
    Smith JR, Rosenbaum JT, Wilson DJ, Doolittle ND, Siegal T, Neuwelt EA (2002) Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 109:1709–1716CrossRefPubMedGoogle Scholar
  12. 12.
    Chan CC, Rubenstein JL, Coupland SE, Davis JL, Harbour JW, Johnston PB, Cassoux N, Touitou V, Smith JR, Batchelor TT, Pulido JS (2011) Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group Symposium. Oncologist 6:1589–1599CrossRefGoogle Scholar
  13. 13.
    Mikami R, Nakayama H, Goto H, Kimura K, Usui Y, Nogi S, Tajima Y, Okubo M, Kanesaka N, Sugahara S, Tokuuye K (2013) Preliminary results of radiotherapy for primary intraocular non-Hodgkin lymphoma. Leuk Lymphoma 54:2181–2184CrossRefPubMedGoogle Scholar
  14. 14.
    Teckie S, Yahalom J (2014) Primary intraocular lymphoma: treatment outcomes with ocular radiation therapy alone. Leuk Lymphoma 55:795–801CrossRefPubMedGoogle Scholar
  15. 15.
    Batchelor TT, Kolak G, Ciordia R, Foster CS, Henson JW (2003) High-dose methotrexate for intraocular lymphoma. Clin Cancer Res 9:711–715PubMedGoogle Scholar
  16. 16.
    Velez G, Yuan P, Sung C, Tansey G, Reed GF, Chan CC, Nussenblatt RB, Robinson MR (2001) Pharmacokinetics and toxicity of intravitreal chemotherapy for primary intraocular lymphoma. Arch Ophthalmol 119:1518–1524CrossRefPubMedGoogle Scholar
  17. 17.
    Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A, Soussain C, DeAngelis LM, Neuwelt EA, O’Neill BP, Thiel E, Shenkier T, Graus F, van den Bent M, Seymour JF, Poortmans P, Armitage JO, Cavalli F, International Primary CNS Lymphoma Collaborative Group (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23:5034–5043CrossRefPubMedGoogle Scholar
  18. 18.
    Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on Lymphoma (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586CrossRefPubMedGoogle Scholar
  19. 19.
    Batchelor T, Carson K, O’Neill A, Grossman SA, Alavi J, New P, Hochberg F, Priet R (2003) Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 21:1044–1049CrossRefPubMedGoogle Scholar
  20. 20.
    Sandor V, Stark-Vancs V, Pearson D, Nussenblat R, Whitcup SM, Brouwers P, Patronas N, Heiss J, Jaffe E, deSmet M, Kohler D, Simon R, Wittes R (1998) Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol 16:3000–3006PubMedGoogle Scholar
  21. 21.
    Nakauchi Y, Takase H, Sugita S, Mochizuki M, Shibata S, Ishiwata Y, Shibuya Y, Yasuhara M, Miura O, Arai A (2010) Concurrent administration of intravenous systemic and intravitreal methotrexate for intraocular lymphoma with central nervous system involvement. Int J Hematol 92:179–185CrossRefPubMedGoogle Scholar
  22. 22.
    Stefanovic A, Davis J, Murray T, Markoe A, Lossos IS (2010) Treatment of isolated primary intraocular lymphoma with high-dose methotrexate-based chemotherapy and binocular radiation therapy: a single-institution experience. Br J Haematol 151:103–106CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Tempescul A, Pradier O, Marianowski-Cochard C, Ianotto JC, Berthou C (2011) Combined therapy associating systemic platinum-based chemotherapy and local radiotherapy into the treatment of primary intraocular lymphoma. Ann Hematol 90:1117–1118CrossRefPubMedGoogle Scholar
  24. 24.
    Grimm SA, Pulido JS, Jahnke K, Schiff D, Hall AJ, Shenkier TN, Siegal T, Doolittle ND, Batchelor T, Herrlinger U, Neuwelt EA, Laperriere N, Chamberlain MC, Blay JY, Ferreri AJ, Omuro AM, Thiel E, Abrey LE (2007) Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Ann Oncol 18:1851–1855CrossRefPubMedGoogle Scholar
  25. 25.
    Riemens A, Bromberg J, Touitou V, Sobolewska B, Missotten T, Baarsma S, Hoyng C, Cordero-Coma M, Tomkins-Netzer O, Rozalski A, Tugal-Tutkun I, Guex-Crosier Y, Los LI, Bollemeijer JG, Nolan A, Pawade J, Willermain F, Bodaghi B, ten Dam-van Loon N, Dick A, Zierhut M, Lightman S, Mackensen F, Moulin A, Erckens R, Wensing B, le Hoang P, Lokhorst H, Rothova A (2015) Treatment strategies in primary vitreoretinal lymphoma: a 17-center European collaborative study. JAMA Ophthalmol 133:191–197CrossRefPubMedGoogle Scholar
  26. 26.
    Frenkel S, Hendler K, Siegal T, Shalom E, Pe’er J (2008) Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol 92:383–388CrossRefPubMedGoogle Scholar
  27. 27.
    Goldberg S, Frenkel S, Blumenthal EZ, Solomon A, Pe’er J (2007) Intraocular lymphoma. Ophthalmology 114:1236–1237CrossRefPubMedGoogle Scholar
  28. 28.
    Hormigo A, Abrey L, Heinemann MH, DeAngelis LM (2004) Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. Br J Haematol 126:202–208CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Wei-Li Ma
    • 1
    • 2
  • Hsin-An Hou
    • 1
  • Ya-Jui Hsu
    • 3
  • Yin-Kai Chen
    • 1
  • Jih-Luh Tang
    • 1
  • Woei Tsay
    • 1
  • Po-Ting Yeh
    • 3
  • Chung-May Yang
    • 3
  • Chang-Ping Lin
    • 3
  • Hwei-Fang Tien
    • 1
    • 4
  1. 1.Division of Hematology, Department of Internal MedicineNational Taiwan University HospitalTaipeiTaiwan
  2. 2.Department of OncologyNational Taiwan University Hospital, Yun-Lin BranchYun-LinTaiwan
  3. 3.Department of OphthalmologyNational Taiwan University HospitalTaipeiTaiwan
  4. 4.Department of Internal MedicineNational Taiwan University HospitalTaipeiTaiwan

Personalised recommendations